{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:37:58Z","timestamp":1794242278811,"version":"4.9.0"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Importance<\/jats:title>\n<jats:p>Herpes zoster infection is common in immunocompromised individuals. Recently, the Advisory Committee on Immunization Practices recommended immunizing with the recombinant zoster vaccine (RZV).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Objective<\/jats:title>\n<jats:p>To evaluate the efficacy, immunogenicity and safety of RZV in immunocompromised individuals, such as transplant recipients, cancer patients undergoing chemotherapy, individuals with preexisting autoimmune diseases and HIV-infected patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Data sources and selection<\/jats:title>\n<jats:p>From January 1984 to October 2023, a systematic search of PubMed, MEDLINE, EMBASE, Scopus, Web of Science, CINAHL, and Cochrane CENTRAL was performed. Randomized clinical trials (RCT) evaluating RZV compared to placebo in immunocompromised adults were selected.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Data extraction<\/jats:title>\n<jats:p>Study characteristics and estimates on the incidence of herpes zoster, immune responses, and safety data were extracted from studies. Estimates were pooled using random-effects meta-analysis. Differences by study-level characteristics were estimated using subgroup meta-analysis and metaregression.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Results<\/jats:title>\n<jats:p>Seven RCTs were included. Compared to placebo, RZV reduced the incidence of herpes zoster across all ages by 81% (RR: 0.19, 95%CI: 0.09, 0.44), with moderate heterogeneity across the studies (I2 = 60.49%; \u03c42 = 0.31; P = 0.07). RZV significantly increased humoral and cellular immunity one month after the last dose. Transplant and past malignancy were associated with lower immunogenicity. RZV was more reactogenic with more local and systemic adverse events. There was no difference in serious adverse events or death between the two arms.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec006\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This study suggests that RZV reduces the risk of herpes zoster infection in immunocompromised individuals. This vaccine should be routinely offered to immunocompromised individuals, preferably before chemotherapy or treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0313889","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T18:36:16Z","timestamp":1732559776000},"page":"e0313889","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":31,"title":["Systematic review and meta-analysis of recombinant herpes zoster vaccine in immunocompromised populations"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1266-1901","authenticated-orcid":true,"given":"Fawziah","family":"Marra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelyn J.","family":"Cragg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5513-7926","authenticated-orcid":true,"given":"Nirma Khatri","family":"Vadlamudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"pone.0313889.ref001","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: herpes zoster","volume":"369","author":"JI Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"pone.0313889.ref002","first-page":"9","article-title":"The nature of herpes zoster: a long-term study and a new hypothesis","volume":"58","author":"RE Hope-Simpson","year":"1965","journal-title":"Proc R Soc Med"},{"key":"pone.0313889.ref003","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1017\/CBO9780511601194.015","volume-title":"Varicella Zoster Virus: Virology and Clinical Management","author":"M. Oxman","year":"2000"},{"issue":"1","key":"pone.0313889.ref004","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.jpain.2007.10.008","article-title":"Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia","volume":"9","author":"RH Dworkin","year":"2008","journal-title":"J Pain"},{"key":"pone.0313889.ref005","unstructured":"Center for Disease Control. Shingles (herpes zoster): clinical overview. Available at: https:\/\/www.cdc.gov\/shingles\/hcp\/clinical-overview.html#epidemiology (accessed Nov 3, 2022)."},{"issue":"22","key":"pone.0313889.ref006","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1056\/NEJMp058091","article-title":"Ageing, immunity, and the varicella-zoster virus","volume":"352","author":"A Arvin","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"pone.0313889.ref007","doi-asserted-by":"crossref","first-page":"ofaa005","DOI":"10.1093\/ofid\/ofaa005","article-title":"Risk factors for herpes zoster infection: A meta-analysis","volume":"7","author":"F Marra","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"pone.0313889.ref008","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/653605","article-title":"Zoster vaccine: current status and future prospects","volume":"51","author":"MN Oxman","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pone.0313889.ref009","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1093\/cid\/ciz1090","article-title":"Herpes zoster risk in immunocompromised adults in the United States: a systematic review","volume":"71","author":"SL McKay","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0313889.ref010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1083-8791(00)70004-8","article-title":"Varicella-Zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients","volume":"6","author":"AM Arvin","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"pone.0313889.ref011","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/sj.bmt.1702119","article-title":"Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation","volume":"25","author":"TF Leung","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"pone.0313889.ref012","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"M Nucci","year":"2009","journal-title":"Clin Infect Dis"},{"key":"pone.0313889.ref013","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/1055-9965.EPI-12-0815","article-title":"The epidemiology of herpes zoster in patients with newly diagnosed cancer","volume":"22","author":"LA Habel","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"pone.0313889.ref014","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.clinthera.2017.07.005","article-title":"A comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients","volume":"39","author":"PP Chong","year":"2017","journal-title":"Clin Ther"},{"key":"pone.0313889.ref015","doi-asserted-by":"crossref","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"K Kawai","year":"2014","journal-title":"BMJ Open"},{"key":"pone.0313889.ref016","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/QAI.0b013e318266cd3c","article-title":"Herpes zoster among persons living with HIV in the current antiretroviral therapy era","volume":"61","author":"LJ Blank","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0313889.ref017","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/clinids\/21.2.370","article-title":"Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus","volume":"21","author":"MJ Glesby","year":"1995","journal-title":"Clin Infect Dis"},{"key":"pone.0313889.ref018","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.qai.0000178408.62675.b0","article-title":"The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era","volume":"40","author":"KA Gebo","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0313889.ref019","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/cid\/cit165","article-title":"Decreasing incidence of herpes zoster in the highly active antiretroviral therapy era","volume":"57","author":"A Moanna","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"6","key":"pone.0313889.ref020","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/infdis\/152.6.1172","article-title":"Infection with varicella-zoster virus after marrow transplantation","volume":"152","author":"RM Locksley","year":"1985","journal-title":"J Infect Dis"},{"issue":"RR-5","key":"pone.0313889.ref021","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"R Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"issue":"ACS-1","key":"pone.0313889.ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14745\/ccdr.v36i00a01","article-title":"Herpes zoster vaccine","volume":"36","author":"National Advisory Committee on Immunization (NACI)","year":"2010","journal-title":"Can Commun Dis Rep"},{"key":"pone.0313889.ref023","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"MN Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"pone.0313889.ref024","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"H Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"pone.0313889.ref025","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"AL Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"pone.0313889.ref026","unstructured":"National Advisory Committee on Immunization (NACI). Updated recommendations on the use of herpes zoster vaccines. Available at: https:\/\/www.canada.ca\/en\/services\/health\/publications\/healthy-living\/updated-recommendations-use-herpes-zoster-vaccines.html (accessed October 25, 2022)."},{"key":"pone.0313889.ref027","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines","volume":"67","author":"KL Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"pone.0313889.ref028","unstructured":"Food and Drug Administration. Shingrix [package insert], revised: 07\/2021. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2021. https:\/\/www.fda.gov\/media\/108597\/download. (accessed October 22, 2022)."},{"key":"pone.0313889.ref029","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 Years: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022","volume":"71","author":"TC Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"pone.0313889.ref030","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"10","key":"pone.0313889.ref031","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta\u2010analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"A Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"pone.0313889.ref032","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"JAC Sterne","year":"2019","journal-title":"BMJ"},{"issue":"14","key":"pone.0313889.ref033","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/sim.6844","article-title":"Low-event-rate meta-analyses of clinical trials: implementing good practices","volume":"35","author":"JJ Shuster","year":"2016","journal-title":"Stat Med"},{"key":"pone.0313889.ref034","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JP Higgins","year":"2003","journal-title":"BMJ"},{"key":"pone.0313889.ref035","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"EA Stadtmauer","year":"2014","journal-title":"Blood"},{"key":"pone.0313889.ref036","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"A Bastidas","year":"2019","journal-title":"JAMA"},{"key":"pone.0313889.ref037","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Zoster-039 Study Group","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"pone.0313889.ref038","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/cncr.31909","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial","volume":"125","author":"Zoster-028 Study Group","year":"2019","journal-title":"Cancer"},{"key":"pone.0313889.ref039","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/cid\/ciz177","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial","volume":"70","author":"Z-041 Study Group","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pone.0313889.ref040","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/rheumatology\/keaa424","article-title":"Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials","volume":"60","author":"AF Dagnew","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"pone.0313889.ref041","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Zoster-015 HZ\/su Study Group","year":"2015","journal-title":"J Infect Dis"},{"issue":"10135","key":"pone.0313889.ref042","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0140-6736(18)30631-7","article-title":"Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"V212 Protocol 001 Trial Team","year":"2018","journal-title":"Lancet"},{"key":"pone.0313889.ref043","volume-title":"Adjuvanted recombinant zoster vaccine (RZV) is the first vaccine to provide durable protection against herpes zoster (HZ) in all age ranges \u226550 years: final analysis of efficacy and safety after 11 years (Y) of follow-up","author":"J Diez-Domingo","year":"2024"},{"issue":"14","key":"pone.0313889.ref044","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.vaccine.2013.01.042","article-title":"Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines","volume":"31","author":"F Tavares Da Silva","year":"2013","journal-title":"Vaccine"},{"key":"pone.0313889.ref045","doi-asserted-by":"crossref","first-page":"978203","DOI":"10.3389\/fimmu.2022.978203","article-title":"Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis","volume":"13","author":"Y Xia","year":"2022","journal-title":"Front Immunol"},{"key":"pone.0313889.ref046","doi-asserted-by":"crossref","first-page":"100397","DOI":"10.1016\/j.jvacx.2023.100397","article-title":"Efficacy and safety of the recombinant zoster vaccine: A systematic review and meta-analysis","volume":"15","author":"R Zeevaert","year":"2023","journal-title":"Vaccine X"},{"issue":"6","key":"pone.0313889.ref047","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant zoster vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure","volume":"73","author":"HS Izurieta","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pone.0313889.ref048","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.cgh.2021.07.023","article-title":"Efficacy of recombinant zoster vaccine in patients with inflammatory bowel disease","volume":"20","author":"N Khan","year":"2021","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0313889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T18:36:32Z","timestamp":1732559792000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0313889"}},"subtitle":[],"editor":[{"given":"Alaa","family":"Atamna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":48,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0313889","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.g001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.g002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.g003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.g004","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.g005","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.t001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.t002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.s002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.s003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.s004","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.s005","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.s006","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.s007","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.s008","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.s009","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.s010","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.s011","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0313889.s012","asserted-by":"subject"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]}}}